newsfilter
← Latest News
PR Newswire·

Seelos Therapeutics Announces the Close of Enrollment of its Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in Adults with Major Depressive Disorder (MDD)

- There is currently no FDA approved treatment for ASIB in MDD. - Top-line data from this study is expected in the third quarter of 2023. NEW YORK, June 22, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL)